Delineation of Stage Specific Expression of *Plasmodium falciparum* EBA-175 by Biologically Functional Region II Monoclonal Antibodies

B. Kim Lee Sim¹*, David L. Narum²*, Rana Chattopadhyay³, Adriana Ahumada¹, J. David Haynes⁴, Steven R. Fuhrmann⁵, Jennifer N. Wingard⁶, Hong Liang⁷, J. Kathleen Moch⁴, Stephen L. Hoffman¹,³

¹ Protein Potential LLC, Rockville, Maryland, United States of America, ² Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America, ³ Sanaria Inc., Rockville, Maryland, United States of America, ⁴ U.S. Military Malaria Vaccine Program, Silver Spring, Maryland, United States of America, ⁵ Intercell USA, Gaithersburg, Maryland, United States of America, ⁶ Department of Molecular Physiology and Biophysics, University of Virginia, Charlottesville, Virginia, United States of America, ⁷ Infectious Disease Research Institute, Seattle, Washington, United States of America

Abstract

**Background:** The malaria parasite *Plasmodium falciparum* EBA-175 binds its receptor sialic acids on glycophorin A when invading erythrocytes. The receptor-binding region (RII) contains two cysteine-rich domains with similar cysteine motifs (F1 and F2). Functional relationships between F1 and F2 domains and characterization of EBA-175 were studied using specific monoclonal antibodies (mAbs) against these domains.

**Methods and Findings:** Five mAbs specific for F1 or F2 were generated. Three mAbs specific for F2 potently blocked binding of EBA-175 to erythrocytes, and merozoite invasion of erythrocytes (IC₅₀ 10 to 100 μg/ml IgG in growth inhibition assays). A mAb specific for F1 blocked EBA-175 binding and merozoite invasion less effectively. The difference observed between the IC₅₀ of F1 and F2 mAbs was not due to differing association and disassociation rates as determined by surface plasmon resonance. Four of the mAbs recognized conformation-dependent epitopes within F1 or F2. Used in combination, F1 and F2 mAbs blocked the binding of native EBA-175 to erythrocytes and inhibited parasite invasion synergistically in vitro. MAB R217, the most potent, did not recognize sporozoites, 3-day hepatocyte stage parasites, nor rings, trophozoites, gametocytes, retorts, ookinetes, and oocysts but recognized 6-day hepatocyte stage parasites, and schizonts. Even though efficient at blocking binding to erythrocytes and inhibiting invasion into erythrocytes, MAB R217 did not inhibit sporozoite invasion and development in hepatocytes in vitro.

**Conclusions:** The role of the F1 and F2 domains in erythrocyte invasion and binding was elucidated with mAbs. These mAbs interfere with native EBA-175 binding to erythrocyte in a synergistic fashion. The stage specific expression of EBA-175 showed that the primary focus of activity was the merozoite stage. A recombinant RII protein vaccine consisting of both F1 and F2 domains that could induce synergistic activity should be optimal for induction of antibody responses that interfere with merozoite invasion of erythrocytes.

Citation: Sim BKL, Narum DL, Chattopadhyay R, Ahumada A, Haynes JD, et al. (2011) Delineation of Stage Specific Expression of *Plasmodium falciparum* EBA-175 by Biologically Functional Region II Monoclonal Antibodies. PLoS ONE 6(4): e18393. doi:10.1371/journal.pone.0018393

Editor: Photini Sinnis, New York University School of Medicine, United States of America

Received November 15, 2010; Accepted February 28, 2011; Published April 14, 2011

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

**Funding:** This work was partially funded by a Phase II National Institute of Allergy and Infectious Diseases (NIAID) Small Business Innovative Research Grant, AI36758 supplement awarded to BKLS. The authors BKLS, DLN, SRF, JNW and HL were employees of EntreMed Inc (funder). Currently BKLS, AA and SLH are employees of Protein Potential (funder) and the role they played on this manuscript was funded by Protein Potential. As the authors BKLS, DLN, SRF, JNW and HL were employees of EntreMed and Protein Potential did have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. RC and SLH are also employees of Sanaria Inc (funder) but their role in this manuscript was funded by Protein Potential. SRF is currently an employee of Intercell but only reviewed the manuscript at this time. Intercell provided no support for this project.

**Competing Interests:** BKLS, AA and SLH are employees of Protein Potential. RC and SLH are employees of Sanaria Inc. SRF is an employee of Intercell. EntreMed, Inc. (funder) and were supported (salaries, equipment, supplies) by the NIAID Small Business Innovative Research Grant AI36758 for their role on this manuscript at that time. EntreMed has no interest on this manuscript. Protein Potential, Sanaria and Intercell had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. BKLS, AA and SLH do not own stocks in Protein Potential nor Sanaria. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.

* E-mail: ksiml@protopot.com

† These authors contributed equally to this work.
**Introduction**

The invasion of erythrocytes by malaria parasites is mediated by specific molecular interactions between erythrocyte receptors and parasite ligands. Within *Plasmodium* sp., a family of erythrocyte binding proteins (EBPs) with signature cysteine rich motifs is involved in binding to erythrocyte receptors for invasion of erythrocytes [1–4] or sequestration of parasitized erythrocytes to endothelial cells [5–7]. EBA-175 is a 175 kDa erythrocyte binding protein [1,4,8,9], that binds erythrocytes via sialic acids on its receptor glycoporphin A. This binding involves recognition of both the sialic acids and the peptide backbone of glycoporphin A [4]. The erythrocyte-binding region of EBA-175 is a 616 amino acid fragment, designated region II (RII) that contains 27 cysteines as tandem duplications of two copies of a cysteine rich domain to form regions F1 and F2 [2]. F1 and F2 are homologous to the Duffy binding protein of *P. vivax* and are also called Duffy binding-like domains (DBL). The presence of one or two DBL domains and other elements including a C-terminal cysteine-rich region and a type I transmembrane domain classifies EBA-175 as a member of the erythrocyte binding-like (EBL) superfamily of proteins [2]. This EBL superfamily includes BAEBL/EBA-140/EBP2 [10–12] MAEBL [13], EBA-181/JESEBL [14] and var genes, a large family of genes regulated by chromatin modification [15,16] that encode antigenically variant proteins including PfEMP-1 [5,7]. PfEMP-1 contains several DBL domains and is involved in the cytoadherence of parasitized erythrocytes to endothelia of microcapillaries causing cerebral malaria and mortality associated with *P. falciparum* [5,7]. Thus the RII of EBA-175 that consists of two DBL domains that appear unique to *Plasmodium* sp. may constitute a good target for rational drug design and vaccines.

Antibodies generated against EBA-175 RII potently block the binding of native EBA-175 to erythrocytes [17–19] and even inhibit invasion of *P. falciparum* strains that invade erythrocytes by pathways that do not require sialic acids for invasion *in vitro* [18]. Further, a DNA prime/recombinant protein boost immunization regimen was shown to protect 3 of 4 *Aotus* monkeys against a lethal *P. falciparum* blood-stage challenge [17]. Immunoglobulin G obtained from the vaccinated *Aotus* monkeys inhibited parasite growth *in vitro* [17]. F2 alone is sufficient for binding to erythrocytes [4]. Indeed, crystallographic studies show that binding to glycoporphin A occurs when a dimer arrangement of RII forms a channel allowing ligand-receptor interaction wherein more than 75% of the sequences within the channel are derived from F2 [20]. The EBA-175 RII DNA vaccine tested in non-human primates [17,19] and recombinant protein vaccine tested in a Phase 1 clinical trial [21] are comprised of both F1 and F2 domains.

In this report we investigated the role of EBA-175 RII F1 and F2 domains in erythrocyte binding and parasite invasion *in vitro* using monoclonal antibodies (mAbs) that specifically recognized F1 or F2 domains, and established the stage specific expression of EBA-175 in the parasite life cycle. Although RII specific mAbs blocked F2 function more efficiently than F1, we show that a combination of F1 and F2 specific mAbs blocked the function of EBA-175 erythrocyte binding and parasite invasion *in vitro*, synergistically.

**Results**

**Characteristics of mAbs generated**

Five mAbs were cloned and identified as R215 through R218 and R256. All the mAbs were identified as belonging to subclass IgG1. These mAbs gave a characteristic apical punctate fluorescence pattern with FVO (Fig. 1A and Table 1) and 3D7 strain (not shown) late stage schizonts. The specificity of the mAbs against EBA-175 was determined by immunoprecipitation of *P. falciparum* [35S]-metabolically labeled schizont stage parasite culture supernatant containing labeled native EBA-175 (Fig. 1B) as well as schizont-infected erythrocyte lysates (not shown). mAbs R216, R217 and R218 recognized a 175 kDa protein, R216 albeit poorly, that was similar in mass to EBA-175 as recognized by rabbit polyclonal anti-EBA-175 RII (KLS15) used as a positive control (Fig. 1B) [18], and negative control KLS15, rabbit polyclonal sera raised against adjuvant alone. The isotype control mAb 48F8, a mAb raised against adjuvant alone did not immunoprecipitate EBA-175 (Fig. 1B). The IFA staining patterns of mAbs R215, R216, R218 and R256 and results of immunoprecipitation with mAbs R215 and R256 were similar to that with mAb R217, respectively (data not shown).

Immunoblot analysis using both reduced and non-reduced conditions showed that mAbs R215 (Fig. 2), R215 and R256 (data not shown) recognized a conformational, disulfide-constrained epitope located within the F2 domain of RII. This is because R217 only recognized non-reduced F2 domain of RII. mAb R218 recognized a conformation-dependent epitope located within the F1 domain of RII because only the F1 domain was recognized. Even though similar quantities of F1 and F2 protein were present in the immunoblot, the recognition was much stronger against non-reduced F1, probably because reduction was incomplete. mAb R216 most probably recognized a linear or unexposed region of the F2 domain of RII because only F2 was recognized. Even though similar quantities of F2 protein were present in the immunoblot, the recognition was much stronger against reduced F2 (Fig. 2). Slight recognition of non-reduced F2 was seen with R216 probably because there was some denaturation and reduction in the material. Further analysis of RII/F2 specific mAbs R215, R216, R217 and R256 demonstrated that R215, R217 and R256 competed with each other for binding recombinant RII protein by competition ELISA (data not shown).

mAbs generated blocked the binding of native EBA-175 to erythrocytes and inhibit invasion and growth of parasites *in vitro*

Differences in the ability of recombinant F1 and F2 domains to bind erythrocytes have been reported [4,22]. When expressed on the surface of COS cells, F2 alone could support the binding and rosetting of erythrocytes on the surface of these COS cells, but not F1 alone [4]. Hence we investigated whether targeting F1 and F2 in combination would have an additive or synergistic effect on blocking of EBA-175 erythrocyte binding. Using IgG concentrations within the range of the IC50’s for R217, R218 and R256 (Table 1), and [35S]-metabolically labeled native EBA-175, blocking of binding studies were performed such that the proportion of mAb R217 equaled one minus the proportion of mAb R218 or R256. mAbs R217 and R256, both against the F2 domain, blocked [35S]-labeled native EBA-175 binding to erythrocytes efficiently with IC50 of 1-15 ng/mL IgG (Fig. 3 and Table 1). The mAb R218 against the F1 domain had a lesser ability to block the binding of native EBA-175 to erythrocytes (IC50 ranged between 25 to 125 ng/mL IgG, (Fig. 3 and Table 1). Interestingly, MAb R216 that recognizes a linear or unexposed epitope essentially could not block binding of native EBA-175 to erythrocytes at the maximal amount of MAb R216 used in our binding assay. In fact, the IC50 was only 14% and 21% at 333 and 666 μg/mL R216 (data not shown). When the F2 specific mAb R217 is proportionally mixed with the F1 specific mAb R218, a synergistic increase in blocking is evident (Fig. 3, panel A). Under
similar conditions, proportional ratios of the mAb R217 mixed with mAb R256 both of which are most probably against a common region in F2 together resulted in an additive effect such that there was no overall increase in blocking (Fig. 3, panel B).

We investigated whether RII specific mAbs conferred growth inhibitory activity (GIA) on the parasite strains 3D7 and FVO. We selected the 3D7 strain that invades neuraminidase-treated erythrocytes, which are devoid of sialic acids, at 70% efficiency as compared to invasion of normal erythrocytes [23], and the FVO strain that is dependent on sialic acids for erythrocyte invasion [18]. The results of 5 separate growth inhibition assays are shown in Table 2 for mAbs R216, R217 and R218 and summarized for the FVO strain in Table 1. GIA results obtained for mAb R256 (data not shown) were similar to mAb R217. A dose dependent effect on parasite growth was observed with mAb R217 against the FVO strain (Fig. 4). The inhibition of parasite growth per cycle of the FVO strain compared to the 3D7 strain was approximately 2-fold greater. The IC50 for mAbs R217 and R256 (data not shown) against FVO ranged between 10 – 100 μg/mL IgG compared to the IC50 against 3D7 which was greater than 1 mg/mL (Table 2). Analysis of experimental conditions such as initial parasitemias and growth rates were similar and thus could not result in the consistent differences in inhibition of parasite growth between FVO and 3D7 strains (data not shown). Additional growth inhibition studies using mAbs R216 and R218, which recognized a linear or hidden epitope within F2 or a conformation-dependent epitope within F1 respectively, demonstrated that both significantly inhibited parasite growth although markedly less than mAb R217 (Table 2).

Association and dissociation rates of mAbs R217 and R218 are similar

Since F1 and F2 domains have different avidities for binding human erythrocytes when transiently expressed on the surface of COS cells [4], we were interested in determining whether these differences could be probed using R218 and R217 that were against domains F1 and F2 respectively. Using surface plasmon resonance, we determined that the association and dissociation rates for mAbs R217 and R218, were similar, \( k_a = 2.35 \times 10^5 \text{M}^{-1}\text{s}^{-1} \) vs \( k_d = 4.47 \times 10^4 \text{s}^{-1} \), and \( k_d = 6.82 \times 10^6 \text{s}^{-1} \), respectively. The difference in the kds would favor a higher affinity for mAb R218 that was not observed in our other assays. The kds for mAbs R217, R218 and R256 which were in the nanomolar or picomolar range are reported in Table 1.

*P. falciparum* sporozoites do not express EBA-175 (Fig. 5)

Immunofluorescence assays using mAb R217 against infectious *P. falciparum* sporozoites harvested from mosquito salivary glands and schizont infected human erythrocytes revealed that EBA-175 is expressed in mature schizonts (Fig. 1 and Fig. 5C), and as described previously [1], but not in sporozoites (Fig. 5B). R217 mAb failed to show any reactivity in IFA with sporozoites even when used at a concentration of 20 μg/mL (data not shown). In contrast, these
sporozoites are recognized strongly by mAb 2A10, specific against *P. falciparum* circumsporozoite protein used at 0.136 μg/mL (Fig. 5A). EBA-175 is expressed in late hepatic stages (6 day) of *P. falciparum*, but not in early (3 day) hepatic stages in vitro (Fig. 5). *P. falciparum* sporozoites when allowed to invade human HCO4 cells [24] in vitro, developed to 6 day liver stage parasites (Fig. 5F). At 6 days after invasion of sporozoites, these liver stage parasites also strongly express MSP-1 (data not shown). In contrast, the earlier liver stage parasites 3 days after invasion of sporozoites, neither express EBA-175 nor MSP-1.

MAb R217 recognized late (6 day) liver stage parasites that are probably merozoites with typical punctate fluorescence (Fig. 5F) prior to erythrocyte rupture, but did not recognize early (3 Day) hepatic stage parasites (Table 3). MAb R217 does not effect the invasion and development of *P. falciparum* sporozoites in human hepatocytes in vitro as assessed by the inhibition of liver stage development assay (ILSDA) (Table 4). In ILSDA, mAb 2A10 against the *P. falciparum* CSP reduced the numbers of parasites expressing PfLSA-1 by 92.83%. In the same assay mAb R217 had no effect on the number of parasites expressing PfLSA-1 (Table 4).

MAb 217 recognizes schizonts but not rings, trophozoites nor male and female gametocytes, retorts, ookinete and oocysts

### Table 1. Summary of EBA-175 RII specific mAbs.

| mAb   | Isotype | IFA (Apical Staining) | Epitope mapping | KD of binding (M) | IC50-blocking EBA-175 binding (ng/ml) | IC50-GIA# |
|-------|---------|------------------------|-----------------|-------------------|----------------------------------------|-----------|
|       |         |                       | RII domain      |                   | Reduced Non-reduced                    |           |
| R215  | IgG1    |                       | F2c\(^1\)       |                   | ND                                     | ND        |
| R216  | IgG1    |                       | F2L             | Poor              | ND                                     | NA        |
| R217  | IgG1    |                       | F2c\(^1\)       |                   | 1.84×10\(^{-9}\) 1–15                   | 10–100 μg/ml |
| R218  | IgG1    |                       | F1c             |                   | 1.53×10\(^{-11}\) 25–125                 | >1 mg/ml  |
| R256  | IgG1    |                       | F2c\(^1\)       |                   | 1.8×10\(^{-10}\) 1–15                    | 10–100 μg/ml |

ND: not determined
NA: not achievable. R216 at 333 and 666 μg/ml IgG blocked EBA-175 binding by 14 and 21%, respectively.

*P. falciparum* FVO 2 cycle suspension growth inhibition assay (GIA).

\(^1\) mAbs compete against each other for binding RII by competition ELISA.

c: constrained epitope; L: linear epitope; immupt: immunoprecipitate.

*incomplete reduction; ** partial denaturation/reduction.

doi:10.1371/journal.pone.0018393.t001

![Figure 2. Immunoblot analysis of EBA-175 RII mAbs against *P. pastoris* expressed recombinant RII F1 or F2 domains.](image)

MAb R216 recognized a linear epitope within the F2 domain reacting against both reduced recombinant RII and F2 domain. MAb R217 recognized an epitope within F2 that was conformationally dependent. Reduction abrogated reactivity of R217 against recombinant RII and the F2 domain. MAb R218 was conformationally dependent and specific against the F1 domain and reacted against non-reduced RII and F1. Purified recombinant baculovirus EBA-175 RII protein at 0.5 μg per lane, or 10 μL per lane of supernatant of *P. pastoris* cultures expressing recombinant EBA-175 RII F1 or F2 domains were separated by SDS-PAGE under reduced or non-reduced conditions and electroblotted onto nitrocellulose membranes. In analyses against R216, a small fraction of the recombinant proteins were slightly denatured or reduced. In analysis using R218, reduction of the recombinant proteins was not absolute. Membranes were probed with 10 μg/mL each of mAbs R216, R217 or R218 separately. A similar staining pattern to that of R217 was observed for mAbs R215 and R256 (data not shown).

doi:10.1371/journal.pone.0018393.g002
Male and female gametocytes of all stages of development (stages I-V), retorts, ookinete and oocysts are also not recognized by mAb 217 but these preparations are all recognized by monoclonal antibody against Pfs25 (from MR4, data not shown)[25].

**Discussion**

RII is a 616 amino acid fragment of EBA-175 that consists of two cysteine-rich Duffy binding-like (DBL) domains (F1 and F2) that are homologous to the RII of Duffy binding protein of *P. vivax*.

EBA-175 RII is the receptor-binding domain that binds sialic acids on its receptor, glycophorin A, on erythrocytes during merozoite invasion. Polyclonal antibodies from mice, rabbits and Aotus monkeys immunized against RII block native EBA-175 binding to erythrocytes and inhibit parasite growth in vitro[1,19]. Here we report on the characterization of a panel of EBA-175 RII specific mAbs that both alone or in combination block the binding of native EBA-175 to erythrocytes and inhibit *P. falciparum* growth in vitro.

Five mAb clones designated R215 through R218 and R256 were developed against a purified baculovirus expressed RII (3D7 strain) protein [22] that recognized either linear (R216) or conformationally dependent (disulfide constrained) epitopes within F1 (R218) or F2 (R215, R217 and R256) as shown by immunoprecipitation (Fig. 1B) and immunoblot (Fig. 2). All of the mAbs recognized *P. falciparum* FVO and 3D7 schizont infected erythrocytes in standard fixed immunofluorescence assays. These strains were selected for testing because 3D7 can invade via sialic acid independent pathway(s) while FVO strictly invade by binding to sialic acids. All but one of the mAbs (R216) effectively blocked native EBA-175 binding and inhibited parasite growth in vitro (Table 1). MAb R216 was incapable of blocking the binding of native EBA-175 to erythrocytes and was also not able to inhibit in GIA (Table 1). The difference seen between mAb R216 and the other biologically active mAbs is likely due to R216 recognizing a linear or hidden epitope.

Reactivity of mAb R216 to reduced recombinant RII in immunoblots show increased recognition as compared to non-reduced recombinant RII (Fig. 2). MAb R218 that recognized the F1 domain inhibited parasite growth considerably less than the F2 domain specific mAbs. Surface plasmon resonance association and dissociation rates revealed nanomolar or greater KDs for mAbs R217, R218 and R256 indicative of high affinity binding (KD: 0.01–1 nM) (Table 1). Thus the observed differences in inhibition of parasite growth by the mAbs were

**Figure 3.** MAb against the F1 and F2 domains block native [35S]-labeled EBA-175 binding to erythrocytes synergistically. Effects of mAbs on immunoprecipitation of [35S]-labeled parasite culture supernatant containing labeled native EBA-175. Panel A shows that ratios of mAb R217 (against F2) and R218 (against F1) together increased the blocking of native EBA-175 binding (a synergistic effect). In contrast, Panel B shows that different ratios of mAb R217 (against F2) and R256 (also against F2) together resulted in similar levels of blocking (an additive effect). R217 and R256 may recognize a common epitope within the F2 domain. Bars show % blocking values as assessed by a phosphoimager.

doi:10.1371/journal.pone.0018393.g003

**Figure 4.** Scatterplot showing a dose effect on *P. falciparum* FVO growth using mAb R217. The solid line shows the linear regression and the dashed lines represent 95% confidence intervals. The goodness of fit $R^2$ was 0.9017.

doi:10.1371/journal.pone.0018393.g004
Inhibitory Monoclonals against EBA-175 Region II

Table 2. Inhibition of growth of *P. falciparum* FVO and 3D7 strains by RII MAbs.

| Exp. | mAb (mg/ml) | FVO infected RBCs (%) | 3D7 infected RBCs (%) |
|------|-------------|-----------------------|-----------------------|
|      |             | 48F8 (Control) | R217 | R216 | 48F8 (Control) | R217 | R216 |
| 1    | 1.0         | 1.64              | 0.28 (59) | 1.53 (4) | 5.43 | 3.29 (22) | 3.97 (14) |
| 2    | 1.0         | 0.56              | 0.11 (57) | 0.43 (13) | 4.16 | 2.11 (29) | 3.09 (14) |
| 3    | 1.0         | 2.26              | 0.36 (60) | ND | 5.38 | 3.16 (23) | ND |
|      | 0.32        | 2.34              | 0.63 (48) | ND | 5.13 | 3.21 (21) | ND |
|      | 0.10        | 2.14              | 0.87 (36) | ND | 5.18 | 3.23 (21) | ND |
|      | 0.03        | 2.40              | 1.52 (20) | ND | 5.41 | 4.14 (12) | ND |
|      | 0.01        | 2.51              | 1.67 (19) | ND | 5.25 | 4.62 (6) | ND |
| 4    | 1.0         | 0.97              | ND | 0.65 (18) | 3.15 | ND | 3.02 (2) |
| 5    | 1.0         | 1.06              | 0.22 (55) | 0.75 (16) | 3.10 | ND | 3.15 (~1) |
|      | 0.5         | 0.26              | 0.04 (60) | 0.19 (14) | 2.94 | ND | 2.82 (2) |
|      | 0.25        | 0.24              | 0.06 (50) | 0.22 (6) | 2.99 | ND | 2.79 (3) |

*Pc*: final parasitemia after two cycles of invasion in presence of control mAb 48F8.

**Pt (Ipc)**: final parasitemia after two cycles of invasion in presence of test mAb (calculated % inhibition per invasion cycle).

The percentage inhibition per cycle was calculated according to the formula: Ipc = 1 – (Pt/Pc).

doi:10.1371/journal.pone.0018393.t002

not due to differences in affinity. It is possible that mAb218, which recognizes the F1 domain, is less able to inhibit parasite invasion because its recognition epitope is a region of F1 that is not involved intimately with receptor binding. Structural studies of RII showed that F1 and F2 domains are very similar, and that RII crystallizes as a dimer which interacts extensively with each other in an antiparallel fashion resembling a handshake [20]. The F1 domain of one monomer interacts directly with the F2 domain of the other monomer. The formation of the RII dimer creates two channels that span the dimer with 75% of the residues that comprise the channel surfaces contributed by the F2 domain. Thus F1 is not physically involved in the binding but stabilizes the RII dimer complex required for docking of EBA-175 as it interacts with its receptor glycophorin A, as described in crystallographic studies [20].

Invasion of erythrocytes by the FVO strain is dependent on the presence of sialic acids on glycophorin A while 3D7 can invade by alternate pathways other than sialic acids. In the case of 3D7, antibodies against RII could nevertheless still significantly block invasion of erythrocytes [18,26]. In this report we show that the F2 specific mAb R217 clearly blocked the invasion of the FVO strain approximately 2-fold greater relative to the 3D7 strain (Table 2). The RII amino acid sequences of the FVO versus the 3D7 strains only differ by 5 out of the 616 amino acid residues (Table 2). The RII amino acid sequences of the FVO versus the 3D7 strains only differ by 5 out of the 616 amino acid residues [27]. We thus argue that the reduced inhibition of invasion is due to the ability of 3D7 parasites to invade erythrocytes via an alternate pathway that does not involve sialic acids. MAb R217, on the other hand blocked the invasion of FVO parasites efficiently since FVO parasites exclusively use sialic acids on glycophorin A for invasion.

EBA-175 is expressed in the micronemes of merozoites in schizonts [28] probably as early as nascent segmenting stages in both liver stage and asexual stage schizonts. It had previously been reported that EBA-175 is expressed in sporozoites, a conclusion from studies of reverse transcription of sporozoite total RNA as well as immunofluorescence of sporozoites using polyclonal antibody raised against a recombinant fragment of EBA-175 [30]. We show that mAb R217 does not recognize sporozoites by IFA (Fig. 5) and does not recognize parasites developing in infected hepatocytes 3 days after infection with *P. falciparum* sporozoites (Table 4), nor developing and mature male and female gametocytes (all stages 1-V), retorts, ookinetes and oocysts. However, EBA-175 is clearly expressed in parasites developing in hepatocytes 6 days after sporozoite infection, at a time when these liver stage schizonts are close to being ready to rupture (Fig. 5F, Table 3). In summary, we find no evidence of sporozoite or early liver stage expression of EBA-175 using our characterized mAbs specific against EBA-175 RII. Our studies use preparations of sporozoites that are aseptic and purified from mosquito salivary gland material produced in conditions that meet regulatory compliance for production of clinical material, and liver assays that are used for assessment of such sporozoites [31]. The sporozoites used are characterized in terms of purity and asepticity...
At this time, we do not have an explanation for the discrepancy between our results and those of Gruner et al [30]. The mAb reagents specific for EBA-175 RII described here if used together with EBA-175-GFP chimeric parasites [32] could be powerful tools that can be used to probe the role of EBA-175 in merozoite invasion of erythrocytes and may lead to the design of improved receptor interfering drugs and vaccines.

Materials and Methods

Ethics Statement

All animal studies were done in compliance with protocols approved by the Animal Care and Use Committee at EntreMed Inc., 9640 Medical Center Dr., Rockville MD 20850, under approved protocol ID No. ENT018.

Figure 5. EBA-175 is expressed in *P. falciparum* schizonts, and late liver stages in human hepatocytes *in vitro*, but not sporozoites. A) Sporozoites stained with anti-PfCSP mAb 2A10 (used at 0.136 µg/mL), B) sporozoites stained with mAb R217 (used at 300 µg/mL), C) schizont stained with mAb R217 (used at 2.34 µg/mL), M: merozoite; A: apical end of the merozoite expressing EBA175, D) schizont stained with anti-PfCSP mAb 2A10 (used at 68 µg/mL). The nuclei were stained with DAPI, E) HC-O4 human hepatocytes stained with anti-*P. falciparum* liver stage antigen-1 (PfLSA-1) polyclonal rabbit serum (1:50 dilution) 6 days post infection with *P. falciparum* sporozoites, F) HC-O4 human hepatocytes stained with mAb R217 (used at 100 µg/mL) 6 days post infection with *P. falciparum* sporozoites. N: nucleus of the hepatocyte; P: liver stage parasite.

doi:10.1371/journal.pone.0018393.g005
Parasites

*Plasmodium falciparum* 3D7 strain and FVO strain (Aotus adapted) were maintained as previously reported [33]. Schizonts were purified on Percoll density gradients [34]. *P. falciparum* FVO strain was metabolically labeled with TRAN 35S-LABEL™ (ICN Radiochemicals, Irvine, CA) as previously described [4]. Cell pellets and supernatant were stored at −70°C for later use.

Animals and immunizations

BALB/c mice were immunized subcutaneously with 50 μg each of purified baculovirus derived RII protein (3D7) [22] in Freund’s complete and incomplete adjuvant as suggested by the manufacturer (Sigma, St. Louis, MO). Mice were immunized on days 0, 14, and 28 and bled on days 21, 12, 26, and 40.

Monoclonal Antibodies

MAbs were produced using spleen cells obtained from BALB/c mice immunized with purified baculovirus recombinant EBA-175 RII protein (3D7) [22], and fused with Sp2/0-Ag14 myeloma cells [35]. Hybridoma culture supernatants were screened by indirect immunofluorescence assay (IFA) against methanol-fixed parasitized (3D7) erythrocytes prepared on 15 well slides. Immunoglobulin G was detected using a goat anti-mouse IgG (γ) chain specific FITC coupled reagent (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD). Supernatants positive by IFA were screened for blocking of [35S]-metabolically labeled EBA-175 erythrocyte binding [4]. Hybridoma cell lines positive by IFA that blocked native 3D7 binding to erythrocytes were cloned twice by limiting dilution. IgG subclasses were determined by ELISA using a mouse monoclonal antibody isotyping kit (Sigma, St. Louis, MO) as suggested by the manufacturer. The specificity and growth inhibitory activity of the rabbit polyclonal antibodies produced against recombinant EBA-175 RII has been reported [18].

**Table 3. Expression of *P. falciparum* EBA-175 in late (6 day) but not in early (3 day) liver stages.**

| Sporozoites/well | Primary Antibody* | Days in culture | Number of liver stages | Mean (liver stages)/well | STDEV | % CV |
|------------------|-------------------|----------------|-----------------------|-------------------------|-------|------|
| 25,000           | PLSA-1            | 3              | 309                   | 342                     | 326   | 325.67 | 16.50 | 5.07% |
|                  | R217              | 3              | 0                     | 0                       | 0     | 0     | 0     | 0.00% |
| 50,000           | PLSA-1            | 6              | 32                    | 57                      | 41    | 43.33 | 12.66 | 29.22 |
|                  | R217              | 6              | 18                    | 26                      | 12    | 18.67 | 7.02  | 37.63 |

*PLSA-1 polyclonal rabbit antibody used at 1:50 dilution and mAb R217 used at 100 ug/mL.*

**Table 4. MAb R217 does not inhibit invasion and development of *P. falciparum* sporozoites in the human hepatocyte line, HC04 as assessed by ILSDA.**

| Test Material               | Number of Parasites Expressing PLSA-1* | % Inhibition (compared to Medium) |
|-----------------------------|----------------------------------------|----------------------------------|
|                             | Well 1       | Well 2       | Well 3       | Mean  | SD    |                |
| Medium (control)            | 309          | 342          | 320          | 325.7 | 16.50 | NA              |
| Anti-PEBA-175 mAb R217 (100 ug/ml) | 367          | 331          | 314          | 337.3 | 27.06 | 0               |
| Anti-PICSP mAb 2A10 (100 ug/ml) | 18           | 30           | 22           | 23.3  | 6.11  | 92.83           |

*PLSA-1 polyclonal rabbit antibody used at 1:50 dilution.*

Immunoprecipitation, immunoblot and erythrocyte blocking of binding studies

Aliquots of approximately 1×10^8 parasitized (3D7) erythrocytes that had been metabolically labeled for 4 hours were extracted in buffer containing 1% Triton X-100, [36,37]. Samples were immunoprecipitated by coupling each mAb to Protein G-Sepharose (GE Healthcare) and the immunoprecipitates were washed as previously described using a buffer containing Triton X-100. The labeled proteins were resolved by SDS-PAGE and detected using a phosphoimager (BioRad Molecular Imager FX, Hercules, CA). Immunoblots using the baculovirus recombinant EBA-175 RII protein as well as recombinant F1 and F2 domains expressed in methylotrophic yeast *Pichia pastoris* were prepared as described previously [22]. EBA-175 erythrocyte blocking of binding studies and the determination of the IC50 for blocking of EBA-175 binding were performed as previously described, respectively [4,17].

**Table 4. MAb R217 does not inhibit invasion and development of *P. falciparum* sporozoites in the human hepatocyte line, HC04 as assessed by ILSDA.**

**Immunofluorescence Assay**

Indirect immunofluorescence assays for screening and selection of monoclonal antibody producing clones were performed essentially as described [12] using mouse or rabbit specific antibodies coupled to Alexa 488 or Alexa 546 (Molecular Probes, Eugene, OR), respectively. For other assays including sporozoites, asexual stages including schizonts, male and female gametocytes, retorts and ookinetes and liver stages, parasites...
were of the NF54 strain. Immunofluorescence assays were performed on 12-well Cell-Line Brand IFAT slides (Erie Scientific), containing air-dried sporozoites, or methanol fixed asexual stages including schizonts, and sexual stage parasites in infected human erythrocytes. For liver stage parasites, slides were incubated in a moist chamber at 37°C for 1 hour with 2 fold diluted (starting from 1:50) monoclonal antibodies, R217 and 2A10 (mAb against PICSP) in 1XPBS containing 1% BSA and 0.001% saponin. Slides were washed three times, five minutes each, with 1X PBS and then incubated for 1 h at 37°C with Alexa Fluor 594 anti-mouse antibody at a dilution of 1:200 in 1XPBS containing 1% BSA and 0.001% saponin. After three washes in 1X PBS, slides were mounted with Vectashield mounting medium and observed under phase contrast at X1000 magnification.

**Surface Plasmon Resonance (BIAcore)**

The KDs for RII binding by mAbs R217, R218 and R256 were determined using a BIAcore 3000 (BIAcore, Piscataway, NJ). Purified recombinant RII was immobilized on the flow cell of a CM5 BIAcore biosensor chip. The running buffer was HSB-P buffer (10 mM HEPES [pH 7.4], 150 mM NaCl, 0.005% polysorbate 20 adjusted to 1 mM MgCl2) (BIAcore). All measurements were determined at 25°C. The Langmuir method from BIAevaluation 3.0 was used for determination of KDs [38].

**Asexual stage parasite growth inhibition studies**

Asexual stage parasite growth inhibition studies were performed as previously described [39]. Briefly, synchronized cultures of *P. falciparum* schizont-infected erythrocytes were mixed with test or control Protein G purified immunoglobulin G (IgG) so that final IgG concentrations were as reported and the hematocrit was 6%. The micro-culture plates were harvested for flow cytometry and stained with Hoechst dye to detect parasite DNA. Percent inhibition was calculated from the mean parasitemias of triplicate test and control wells as 100 × (control – test)/control. Polyclonal rabbit anti-EBA-175 RII IgG was used as a positive control for all experiments (data not shown) [18].

**In vitro Inhibition of Liver Stage Development Assay (ILSDA)**

ILSDA was performed as described previously [40,41] with some modifications. 4 × 10⁴ human hepatocyte HC-O4 [24] cells in D-MEM/F12 complete medium containing 10% fetal bovine serum were seeded in each well of 8-well LabTek slides. After about 16 hours, medium were aspirated from the wells and serum were seeded in each well of 8-well LabTek slides. After 3 days, wells were fixed and stained with either rabbit polyclonal antiserum against *P. falciparum* LSA-1 (1:50 dilution) followed by Alexa Fluor 488 anti-rabbit antibody or mAb R217 (100 ug/mL), followed by Alexa Fluor 488 anti-mouse antibody and assessed as mentioned above. The numbers of parasites expressing PLSA-1 or PiEBA-175 in each well were counted.

**Expression of EBA-175 in hepatic stages of *P. falciparum* in human hepatocytes in vitro**

**Early hepatic stage (3 day) assay.** LabTek chamber slide wells were seeded with 4 × 10⁴ HC-O4 cells. After twenty four hours, 25,000 sporozoites were added to each well. Washing and processing of slides were as described in the ILSDA above. After 3 days, wells were fixed and stained with either rabbit polyclonal antiserum against *P. falciparum* LSA-1 (1:50 dilution) followed by Alexa Fluor 488 anti-rabbit antibody or R217 (100 ug/mL), followed by Alexa Fluor 488 anti-mouse antibody and assessed as mentioned above. The numbers of parasites expressing PLSA-1 or PiEBA-175 in each well were counted.

**Late hepatic stage (6 day) assay.** LabTek chamber slide wells were seeded with 4 × 10⁴ HC-O4 cells. After twenty four hours, 50,000 sporozoites were added to each well, and processed and maintained as above. After 6 days, wells were fixed and stained with either rabbit antiserum against *P. falciparum* LSA-1 (1:50 dilution) followed by Alexa Fluor 488 anti-rabbit antibody or mAb R217 (100 ug/mL), followed by Alexa Fluor 488 anti-mouse antibody and assessed as mentioned above. The numbers of parasites expressing PLSA-1 or PiEBA-175 in each well were counted.

**Acknowledgments**

We gratefully acknowledge Tin Lau (EntreMed) for screening of hybrid supernatants, Dr. Chia-Wei Tsai for assistance (EntreMed), and Douglas Smoot (Immun Cell Biology Program, Naval Medical Research Center, Bethesda, MD) for performing UV flow cytometry. From Protein Potential, we thank Maria Orozco for assistance with IFAs, and Dr. Minglin Li and Lixin Gao for purified sporozoites. We thank especially Yonas Abebe for help with the manuscript, and Dr. Tao Li, Dr. Abrahim Eappen and the staff at Sanaria Inc. for producing all stages of the parasite life cycle. The EBA-175 RII monoclonal antibody producing clones have been deposited in ATCC MR4.

**Author Contributions**

Conceived and designed the experiments: BKLS DLN SLH. Performed the experiments: RC AA JDH SRF JNW HL JKM. Analyzed the data: BKLS DLN SLH. Contributed reagents/materials/analysis tools: JKM SLH. Wrote the paper: BKLS DLN SLH.

**References**

1. Sim BK, Orlandi PA, Haynes JD, Klotz FW, Carter JM, et al. (1990) Primary structure of the 175K Plasmodium falciparum erythrocyte binding antigen and identification of a peptide which elicits antibodies that inhibit malaria merozoite invasion. J Cell Biol 111: 1077–1084.
2. Adams JH, Sim BKL, Dolan SA, Fang X, Kaslow DC, et al. (1992) A family of erythrocyte binding proteins of malaria parasites. Proceedings of the National Academy of Sciences 89: 7085–7089.

3. Chitnis CE, Miller LH (1994) Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion. J Exp Med 180: 497–506.

4. Sim BK, Chitnis CE, Wasiowska K, Hadley TJ, Miller LH (1994) Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum. Science 263: 1941–1945.

5. Baruch DL, Pasolooke BL, Singh HB, Bi X, Ma XC, et al. (1995) Cloning the P. falciparum gene encoding PFMPI, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes. Cell 82: 77–87.

6. Smith JD, Chitnis CE, Craig AG, Roberts DJ, Hudson-Taylor DE, et al. (1995) Identification of the erythrocyte binding domains of Plasmodium falciparum. Science 268: 289–295.

7. Su XZ, Houwasse VM, Wertheimer SP, Guinet F, Heerfeldt JA, et al. (1995) The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of Plasmodium falciparum-infected erythrocytes. Cell 82: 89–100.

8. Camusz D, Hadley TJ (1995) A Plasmodium falciparum antigen that binds to host erythrocytes and merozoites. Science 230: 555–556.

9. Orlando PA, Sim BK, Chalud J, Haynes JD (1990) Characterization of the 175-kilodalton erythrocyte binding antigen of Plasmodium falciparum. Mol Biochem Parasitol 40: 285–295.

10. Mayer DC, Kaneko O, Hudson-Taylor DE, Reid ME, Miller LH (2001) Intracellular proteolysis mediates shedding of a key adhesin during erythrocyte invasion by the malaria parasite. J Cell Biol 147: 1023–1033.

11. Thompson JK, Triglia T, Cowman AF (2001) A novel ligand from Plasmodium falciparum erythrocyte-binding protein paralogue to EBA-175. Proc Natl Acad Sci U S A 98: 5222–5227.

12. Thompson JK, Triglia T, Reed MB, Cowman AF, Gilberger TW (2001) A novel Plasmodium falciparum erythrocyte-binding protein-2 (EBP2/BAEB1) involved in erythrocyte binding. Mol Biochem Parasitol 115: 139–146.

13. Blair PL, Kappe SH, Maciej JE, Bahu B, Adams JH (2002) Plasmodium falciparum MAEB1 is a unique member of the ebl family. Mol Biochem Parasitol 122: 35–44.

14. O’Donnell RA, Hackett F, Howell SA, Treeck M, Struck N, et al. (2006) Intramembrane proteolysis mediates shedding of a key adhesin during erythrocyte invasion by the malaria parasite. J Cell Biol 174: 1023–1033.

15. Duraisingh MT, Voss TS, Marty AJ, Duffy MF, Good RT, et al. (2005) Telomeric heterochromatin propagation in Plasmodium vivax and Plasmodium knowlesi parasites. Mol Biochem Parasitol 135: 70–78.

16. Narum DL, Haynes JD, Fuhrmann SR, Moch K, Liang H, et al. (2000) Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA vaccine. Mol Med 7: 247–254.

17. Jones TR, Narum DL, Gozalo AS, Aguiar J, Fuhrmann SR, et al. (2000) Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen. The Journal of infectious diseases 183: 303–312.

18. Narum DL, Haynes JD, Fuhrmann S, Moch K, Liang H, et al. (2000) Antibodies against the Plasmodium falciparum receptor binding domain of EBA-175 block invasion pathways that do not involve sialic acids. Infect Immun 68: 1964–1966.

19. Sim BK, Narum DL, Liang H, Fuhrmann SR, Ohadla N, et al. (2001) Induction of biologically active antibodies in mice, rabbits, and monkeys by Plasmodium falciparum EBA-175 region II DNA vaccine. Mol Med 7: 247–254.

20. Tolia NH, Enemark EJ, Sim BKL, Joshua-Tor L (2005) Structural basis for the EBA-175 erythrocyte invasion pathway of the malaria parasite Plasmodium falciparum. Cell 122: 183–193.